Physician profile
Sanjeev M Wasan
NPI 1093813990
$6,652.61
in general payments reported to CMS, 2019-2025
34 companies · $951 in 2025
The $951 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,171 · 2020: $932 · 2021: $1,295 · 2022: $694 · 2023: $651 · 2024: $959 · 2025: $951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,560.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,165.63 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $1,092.71 | 2019-2025 | Linzess, Viberzi, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $685.89 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $513.66 | 2019-2025 | Stelara, Tremfya |
| Pfizer INC. | $368.73 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $315.33 | 2021-2023 | |
| Madrigal Pharmaceuticals | $238.56 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $234.62 | 2021-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $212.07 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $167.82 | 2022-2023 | |
| Allergan, INC. | $154.31 | 2019-2020 | |
| Boston Scientific Corporation | $139.53 | 2024 | X-Tack Endoscopic Helix Tacking System |
| Celgene Corporation | $126.76 | 2021-2023 | Zeposia |
| Novo Nordisk INC | $121.35 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $121.22 | 2022-2025 | Dupixent |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $119.67 | 2019-2023 | Sutab |
| Enterra Medical, INC. | $117.64 | 2024 | |
| Vivus LLC | $96.91 | 2019-2025 | Qsymia, Pancreaze |
| Ipsen Biopharmaceuticals, INC | $91.15 | 2024-2025 | Bylvay, Iqirvo |
| Ironwood Pharmaceuticals, INC | $85.80 | 2020-2021 | |
| Intercept Pharmaceuticals, INC. | $64.73 | 2019-2020 | |
| Lilly USA, LLC | $62.75 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $60.89 | 2020-2025 | |
| Phathom Pharmaceuticals, INC. | $49.04 | 2024-2025 | Voquezna |
| Alfasigma USA, INC. | $42.23 | 2020 | |
| Covidien LP | $39.01 | 2019 | |
| Redhill Biopharma INC. | $29.51 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $24.89 | 2025 | Zenpep |
| Sandoz INC. | $22.78 | 2023 | Hyrimoz |
| Ucb, INC. | $22.19 | 2019 | |
| Ferring Pharmaceuticals INC. | $19.78 | 2019 | |
| Alnylam Pharmaceuticals INC. | $15.89 | 2021 | |
| Celltrion USA INC. | $15.38 | 2025 | Vegzelma |
| Mylan Institutional INC. | $14.18 | 2023 | Hulio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjeev Wasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.